Status:
COMPLETED
Study Evaluating Etanercept for the Treatment of Active, Severe, and Advanced Axial Ankylosing Spondylitis
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Ankylosing Spondylitis
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
Evaluation of the efficacy and safety of etanercept (Enbrel) in patients with active, severe and advanced ankylosing spondylitis.
Eligibility Criteria
Inclusion
- Inclusion criteria
- Active and severe ankylosing spondylitis
- Ankylosing spondylitis refractory to standard anti-rheumatic treatment
- Between 18 and 70 years of age
- Exclusion criteria
- Prior exposure to any TNF-inhibitor, including etanercept
- DMARDs (other than hydroxychloroquine, methotrexate and sulphasalazine) within 4 weeks of study drug initiation
- Dose of NSAIDs changed within two weeks of study drug initiation
Exclusion
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
82 Patients enrolled
Trial Details
Trial ID
NCT00420238
Start Date
January 1 2007
End Date
May 1 2009
Last Update
June 29 2010
Active Locations (21)
Enter a location and click search to find clinical trials sorted by distance.
1
Amiens, France, 80094
2
Arles, France, 13200
3
Avignon, France, 84000
4
Bordeaux, France, 33076